Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow BMY
Bristol Myers Squibb Company (BMY) Net income
Bristol Myers Squibb Company's net income for fiscal 2025 was $7.1B, compared with −$8.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $9.3B. Over the past ten years it has ranged from −$9.0B (fiscal 2020) to $8.0B (fiscal 2023); the current reading is higher than 91% of that period. Bristol Myers Squibb Company ranks 6th of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $7.1B | — |
| FY2024 | −$8.9B | — |
| FY2023 | $8.0B | 26.71% |
| FY2022 | $6.3B | (9.54%) |
| FY2021 | $7.0B | — |
| FY2020 | −$9.0B | — |
| FY2019 | $3.5B | (30.06%) |
| FY2018 | $4.9B | 407.38% |
| FY2017 | $975.0M | (78.37%) |
| FY2016 | $4.5B | 176.33% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $3.3B | 23.82% |
| Mar 2026 | $2.7B | 146.82% |
| Dec 2025 | $1.1B | (50.57%) |
| Sep 2025 | $2.2B | 67.17% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S compare | $17.9B |
| NVS Novartis AG compare | $12.7B |
| AZN AstraZeneca PLC compare | $12.6B |
| BMY Bristol Myers Squibb Company | $9.3B |
| AMGN Amgen Inc. compare | $8.7B |
| GSK GSK PLC Sponsored ADR compare | $6.9B |
| SNY Sanofi compare | $4.5B |
| PFE Pfizer Inc. compare | $4.4B |
| GILD Gilead Sciences, Inc. compare | −$3.2B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BMY
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement